在伴有肝纤维化的 NASH 中，resmetirom 在 1 年内改善了 NASH 缓解率并降低了纤维化程度。
In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y.
机构信息
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA (M.M.).
Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Maryland, USA (A.H.S.).
出版信息
Ann Intern Med. 2024 Jun;177(6):JC63. doi: 10.7326/ANNALS-24-00206-JC. Epub 2024 Jun 4.
PMID:38830210
Abstract
Harrison SA, Bedossa P, Guy CD, et al. MAESTRO-NASH Investigators. N Engl J Med. 2024;390:497-509. 38324483.
摘要
哈里森 SA、贝多萨 P、盖伊 CD 等人。MAESTRO-NASH 研究人员。新英格兰医学杂志。2024；390:497-509. 38324483.
Zotero 插件